Nitrosylated human serum albumin (SNO-HSA) induces apoptosis in tumor cells

Nitric Oxide - Biology and Chemistry

Volumn 22, Issue 4, 2010, Pages 259-265

  Katayama, Naohisa ^a,b   Nakajou, Keisuke ^b   Ishima, Yu ^a   Ikuta, Shotaro ^b   Yokoe, Jun ichi ^b   Yoshida, Fumika ^a   Suenaga, Ayaka ^a   Maruyama, Toru ^a   Kai, Toshiya ^a,b   Otagiri, Masaki ^a,c  

^a KUMAMOTO UNIVERSITY   (Japan)

^b Nipro Corporation   (Japan)

^c SOJO UNIVERSITY   (Japan)

Author keywords

Anti tumor effect; Apoptosis; Cancer; Nitric oxide; Nitrosylation; SNO HSA

Indexed keywords

CASPASE 3; RECOMBINANT HUMAN SERUM ALBUMIN; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL TYPE; CHEMOPROPHYLAXIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DEPOLARIZATION; DNA FRAGMENTATION; DOSE RESPONSE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; MALE; MITOCHONDRION; NITROSYLATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; RAT; SARCOMA CELL; TUMOR CELL; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; MALE; NITRIC OXIDE; NITROSO COMPOUNDS; RATS; RATS, INBRED STRAINS; SERUM ALBUMIN;

MURINAE; RATTUS;

EID: 77949884806     PISSN: 10898603     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.niox.2009.09.003     Document Type: Article

References (32)

1. Okada H., and Mak T.W. Pathways of apoptotic and non-apoptotic death in tumor cells. Nat. Rev. Cancer 4 (2004) 592-603
2. Meng X.W., Lee S.H., and Kaufmann S.H. Apoptosis in the treatment of cancer: a promise kept?. Curr. Opin. Cell Biol. 18 (2006) 668-676
3. Kaufmann S.H., and Gores G.J. Apoptosis in cancer: cause and cure. Bioessays 22 (2000) 1007-1017
4. Kondo Y., Kanzawa T., Sawaya R., and Kondo S. The role of autophagy in cancer development and response to therapy. Nat. Rev. Cancer 5 (2005) 726-734
5. Brune B., Sandau K., and Knethen A.V. Apoptotic cell death and nitric oxide: activating and antagonistic transducing pathways. Biochemistry (Mosc.) 63 (1998) 817-825
6. Moncada S., and Higgs A. The l-arginine-nitric oxide pathway. N. Engl. J. Med. 329 (1993) 2002-2012
7. Ignarro L.J. Endothelium-derived nitric oxide - pharmacology and relationship to the actions of organic nitrate esters. Pharmacol. Res. 6 (1989) 651-659
8. Azuma H., Ishikawa M., and Sekizaki S. Endothelium-dependent inhibition of platelet aggregation. Br. J. Pharmacol. 88 (1986) 411-415
9. Garthweite J. Glutamate, nitric oxide and cell-cell signaling in the nervous system. Trends Neurosci. 14 (1991) 60-67
10. Marletta M.A., Yoon P.S., Iyengar R., Leaf C.D., and Wishnok J.S. Macrophage oxidation of l-arginine to nitrite and nitrate-nitric oxide is an intermediate. Biochemistry 27 (1988) 8706-8711
11. Laval F., and Wink D.A. Inhibition by nitric oxide of the repair protein, O6-methyl-gluanine-DNA-methyltransferase. Carcinogenesis 15 (1994) 443-447
12. Hibbs Jr. J.B., Taintor R.R., Vavrin Z., and Rachlin E.M. Nitric oxide: a cytotoxic activated macrophage effector molecule. Biochem. Biophys. Res. Commun. 157 (1988) 87-94
13. Beckman J.S., and Crow J.P. Pathological implication of nitric oxide, superoxide and peroxnitrite formation. Biochem. Soc. Trans. 21 (1993) 330-334
14. Qiang L., Chan S.T.F., and Mahendran R. Nitric oxide induces cyclooxygenase expression and inhibits cell growth in colon cancer cell lines. Carcinogenesis 24 (2003) 637-642
15. Fabbri F., Brigliadori G., Ulivi P., Tesei A., Vannini I., Rosetti M., Bravaccini S., Amadori D., Bolla M., and Zoli W. Pro-apoptotic effect of a nitric oxide-donating NSAID, NCX4040, on bladder carcinoma cells. Apoptosis 10 (2005) 1095-1103
16. Kashifi K., Ryann Y., Qiao L.L., Williams J.L., Chen J., Soldato P.D., Traganos F.T., and Rigas B. Nitric oxide-donating nonsteroidal anti-inflammatory drugs inhibit the growth of various cultured human cancer cells: evidence of a tissue type-independent effect. J. Pharmacol. Exp. Ther. 303 (2002) 1273-1282
17. Williams J.L., Borgo S., Hasan I., Castillo E., Traganos F., and Rigas B. Nitric oxide-releasing nonsteroidal anti-inflammatory drugs (NSAIDs) alter the kinetics of human colon cancer cell lines more effectively than traditional NSAIDs: implication for colon cancer chemoprevention. Cancer Res. 61 (2001) 3285-3289
18. Stamler J.S., Jaraki O., Osborne J., Simon D.I., Keaney J., Vita J., Singel D., Valeri C.R., and Loscalzo J. Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin. Proc. Natl. Acad. Sci. USA 89 (1992) 7674-7677
19. Peters Jr. T. Serum albumin. Adv. Protein Chem. 37 (1985) 161-245
20. Katayama N., Nakajou K., Komori H., Uchida K., Yokoe J.I., Yasui N., Yamamoto H., Kai T., Sato M., Nakagawa T., Takeya M., Maruyama T., and Otagiri M. Design and evaluation of S-nitrosylated human serum albumin as a novel anticancer drug. J. Pharmacol. Exp. Ther. 325 (2008) 69-76
21. Matsushita S., Ishima Y., Chuang V.T., Watanabe H., Tanase S., Maruyama T., and Otagiri M. Functional analysis of recombinant human serum albumin domains for pharmaceutical applications. Pharm. Res. 10 (2004) 1924-1932
22. Chen R.F. Removal of fatty acids from serum albumin by charcoal treatment. J. Biol. Chem. 242 (1967) 173-181
23. Habeeb A.F. Determination of free amino groups in proteins by trinitrobenzene-sulfonic acid. Anal. Biochem. 14 (1966) 328-336
24. Ishiyama M., Tominaga H., Shiga M., Sasamoto K., Ohkura Y., and Ueno K. A combined assay of cell viability and in vitro cytotoxicity with a highly water-soluble tetrazolium salt, neutral red and crystal violet. Biol. Pharm. Bull. 19 (1996) 1518-1520
25. Shimizu K., Asai T., Fuse C., Sadzuka Y., Sonobe T., Ogino K., Taki T., Tanaka T., and Oku N. Applicability of anti-neovascular therapy to drug-resistant tumor: suppression of drug-resistant P388 tumor growth with neovessel-targeted liposomal adriamycin. Int. J. Pharm. 296 (2005) 133-141
26. Tanda S., Hori K., Zhang Q.H., Li H.C., and Suzuki M. Effects of intravenous infusion of dopamine on tumor blood flow in rats subcutis. Jpn. Cancer Res. 85 (1994) 556-562
27. Ogawara K.I., Un K., Minato K., Tanaka K.I., Higaki K., and Kimura T. Determinants for in vivo anti-tumor effects of PEG liposomal doxorubicin: importance of vascular permeability within tumors. Int. J. Pharm. 359 (2008) 234-240
28. Katsumi H., Nishikawa M., Yamashita F., and Hashida M. Development of polyethylene glycol-conjugated poly-s-nitrosated serum albumin, a novel s-nitrosothiol for prolonged delivery of nitric oxide in the blood circulation in vivo. J. Pharmacol. Exp. Ther. 314 (2005) 1117-1124
29. Matsumura Y., Oda T., and Maeda H. General mechanism of intratumor accumulation of macromolecules: advantage of macromolecular therapeutics. Jpn. J. Cancer Chemother. 14 pt. II (1987) 821-829
30. Mebmer U.K., Reimer D.M., and Brune B. Nitric oxide-induced apoptosis: p53-dependent and p53-independent signaling pathways. Biochem. J. 319 (1995) 299-305
31. Ishima Y., Sawa T., Kragh-Hansen U., Miyamoto Y., Matsushita S., Akaike T., and Otagiri M. S-nitrosylation of human variant albumin Liprizzi (R410C) confers potent antibacterial and cytoprotective properties. J. Pharmacol. Exp. Ther. 320 (2007) 969-977
32. Mohr S., Zech B., Lapetina E.G., and Brune B. Inhibition of caspase-3 by S-nitrosation and oxidation caused by nitric oxide. Biochem. Biophys. Res. Commun. 238 (1997) 387-391